Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review
- PMID: 32933887
- DOI: 10.1016/j.euo.2020.08.005
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review
Abstract
Context: Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear.
Objective: To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients. The secondary aim was to identify the most relevant prognostic factors to guide the management of pN1 patients.
Evidence acquisition: A systematic review was performed in January 2020 using Medline, Embase, and other databases. A total of 5063 articles were screened, and 26 studies including 12 537 men were selected for data synthesis and included in the current review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) recommendations.
Evidence synthesis: Ten-year biochemical recurrence (BCR)-free, clinical recurrence-free, cancer-specific (CSS), and overall (OS) survival rates ranged from 28% to 56%, 70% to 92%, 72% to 98%, and 60% to 87.6%, respectively. A total of seven, five, and six studies assessed the oncological outcomes of observation, adjuvant radiotherapy (aRT), or adjuvant androgen deprivation therapy (ADT), respectively. Initial observation followed by salvage therapies at the time of recurrence represents a safe option in selected patients with a low disease burden. The use of aRT with or without ADT might improve survival in men with locally advanced disease and a higher number of positive nodes. Risk stratification according to pathological Gleason score, number of positive nodes, pathological stage, and surgical margins status is the key to risk stratification and selection of the optimal postoperative therapy. Limitations of this systematic review are the retrospective design of the studies included and the lack of data on adverse events.
Conclusions: While the majority of men with pN1 disease would experience BCR after surgery, long-term disease-free survival has been reported in selected patients. Management options to improve oncological outcomes include observation versus adjuvant therapies such as aRT and/or ADT. Disease characteristics should be used to select the optimal postoperative management for pN1 PCa patients.
Patient summary: Finding node-positive prostate cancer after a radical prostatectomy often leads to high postoperative prostate-specific antigen levels and is overall a poor prognostic factor. However, this does not necessarily translate into poor survival for all men. Management can be tailored to the severity of disease and options include observation, androgen deprivation therapy, and/or radiotherapy.
Keywords: Lymph node; Positive nodes; Prostate cancer; Radical prostatectomy.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.Eur Urol. 2017 Feb;71(2):249-256. doi: 10.1016/j.eururo.2016.05.008. Epub 2016 May 18. Eur Urol. 2017. PMID: 27209538
-
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31. Eur Urol. 2016. PMID: 26749093
-
Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.Eur Urol. 2009 May;55(5):1003-11. doi: 10.1016/j.eururo.2009.01.046. Epub 2009 Feb 4. Eur Urol. 2009. PMID: 19211184
-
A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.Eur Urol Oncol. 2019 May;2(3):294-301. doi: 10.1016/j.euo.2019.02.001. Epub 2019 Mar 23. Eur Urol Oncol. 2019. PMID: 31200844
-
Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence.Curr Opin Urol. 2022 Jan 1;32(1):69-84. doi: 10.1097/MOU.0000000000000946. Curr Opin Urol. 2022. PMID: 34812201
Cited by
-
Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer.Bioengineered. 2021 Dec;12(1):325-340. doi: 10.1080/21655979.2020.1867405. Bioengineered. 2021. PMID: 33356818 Free PMC article.
-
Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?Cancers (Basel). 2022 May 8;14(9):2326. doi: 10.3390/cancers14092326. Cancers (Basel). 2022. PMID: 35565455 Free PMC article. Review.
-
Role of lymphatic invasion in predicting biochemical recurrence after radical prostatectomy.Front Oncol. 2023 Sep 11;13:1226366. doi: 10.3389/fonc.2023.1226366. eCollection 2023. Front Oncol. 2023. PMID: 37752996 Free PMC article.
-
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy.Prostate Cancer Prostatic Dis. 2024 Mar;27(1):81-88. doi: 10.1038/s41391-022-00619-1. Epub 2022 Nov 25. Prostate Cancer Prostatic Dis. 2024. PMID: 36434164
-
Hotspots and frontiers in PSMA research for prostate cancer: a bibliometric and visualization analysis over the past 20 years.Eur J Med Res. 2023 Dec 19;28(1):610. doi: 10.1186/s40001-023-01590-w. Eur J Med Res. 2023. PMID: 38115121 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous